Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. RL, AMP, HALO and NVDA are some such stocks.

Zacks Investment Research • Aug 19, 2026

Halozyme Appoints Dannielle Appelhans to its Board of Directors

SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management.

PRNewsWire • Aug 18, 2026

Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?

Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Zacks Investment Research • Aug 13, 2026

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Aug 13, 2026

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.

Zacks Investment Research • Aug 7, 2026

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics NASDAQ: HALO reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements.

MarketBeat • Aug 7, 2026

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37% Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43% Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95% 1 Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117% 1 Signed Five New ENHANZE ® and Hypercon ™ Collaboration Agreements YTD 2026, Exceeding Goal of Three for Full Year 2026 SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2026, and provided an update on its recent corporate activities. "We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues," said Dr. Helen Torley, President and Chief Executive Officer.

PRNewsWire • Aug 6, 2026

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 6, 2026